Evidence map›Paper›PMID 31445275›Full record

ArticleInternational journal of medical informatics2019

Augmented intelligence with natural language processing applied to electronic health records for identifying patients with non-alcoholic fatty liver disease at risk for disease progression.

Tielman T Van Vleck, Lili Chan, Steven G Coca, Catherine K Craven, Ron Do, Stephen B Ellis, Joseph L Kannry, Ruth J F Loos, Peter A Bonis, Judy Cho and 1 more

Open access · greenAbstract read
In one paragraph

Article in International journal of medical informatics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 5 pooled it
4.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 5 syntheses or guidelines pooled it, 59 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Observational
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Tielman T Van VleckThe Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, USA. Electronic address: tielman.vanvleck@mssm.edu.
Lili ChanDivision of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, USA.
Steven G CocaDivision of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, USA.
Catherine K CravenInstitute for Healthcare Delivery Science, Dept. of Pop. Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, USA; Clinical Informatics Group, IT Department, Mount Sinai Health System, New York, USA.
Ron DoThe Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, USA.
Stephen B EllisThe Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, USA.
Joseph L KannryInformation Technology, Mount Sinai Medical Center, New York, USA.
Ruth J F LoosThe Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, USA.
Peter A BonisDivision of Gastroenterology, Tufts Medical Center, Boston, USA.
Judy ChoThe Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, USA; Department of Genetics and Genomics, Icahn School of Medicine at Mount Sinai, New York, USA; Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, USA.
Girish N NadkarniThe Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, USA; Division of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, USA. Electronic address: girish.nadkarni@mountsinai.org.
Icahn School of Medicine at Mount Sinai · USMount Sinai Medical Center · USTufts Medical Center · US

Funding

Incorporating genomics into the clinical care of diverse NYC childrenU01HG009610 · NHGRI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GELB, BRUCE D, HOROWITZ, CAROL R · 2017 to 2021
$17.0M
Novel Biomarkers in Cardiac Surgery to Detect Acute Kidney InjuryR01HL085757 · NHLBI · YALE UNIVERSITY · PI PARIKH, CHIRAG R · 2007 to 2019
$10.3M
Multi-Omics and Chronic Kidney Disease: Correlation with HistologyR01DK108803 · NIDDK · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Morgan Erika Grams, EUGENE P. RHEE · 2016 to 2026
$6.4M
Genomic Medicine Pilot For Hypertension And Kidney Disease In Primary CareU01HG007278 · NHGRI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HOROWITZ, CAROL R · 2013 to 2018
$5.7M
Mount Sinai Nephrology Research Training GrantT32DK007757 · NIDDK · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI CAMPBELL, KIRK N, HE, JOHN CIJIANG · 1998 to 2022
$3.8M
Novel serum and urinary biomarkers of diabetic kidney diseaseR01DK096549 · NIDDK · YALE UNIVERSITY · PI COCA, STEVEN G · 2012 to 2016
$2.9M
North East Consortium for Transplant outcomes in APOL1 kidney Recipients (NECTAR) Clinical CenterU01DK116100 · NIDDK · WEILL MEDICAL COLL OF CORNELL UNIV · PI Darshana Dadhania, Samira Farouk · 2017 to 2026
$2.5M
Impact of early antiretroviral therapy on kidney disease outcomesR01DK112258 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI WYATT, CHRISTINA M · 2017 to 2021
$2.1M
Essential Autolysin Activity in Gram-positive BacteriaR01GM106085 · NIGMS · WESTERN UNIVERSITY OF HEALTH SCIENCES · PI SZURMANT, HENDRIK · 2013 to 2017
$1.7M
Linking the Effects of 9/11 to Kidney DiseaseU01OH011326 · OH · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI MCLAUGHLIN, MARY A · 2017 to 2019
$1.5M
Leveraging Clinical Trials of Diabetic Kidney Disease to Advance BiomarkersU01DK106962 · NIDDK · YALE UNIVERSITY · PI COCA, STEVEN G, PARIKH, CHIRAG R · 2015 to 2019
$1.3M
Risk Clustering and Stratification in Genetically High-Risk Individuals Using Electronic Medical Records and BiomarkersK23DK107908 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI NADKARNI, GIRISH NITIN · 2016 to 2020
$930k
NHGRI NIH HHS U01 HG007278NHGRI NIH HHS U01 HG009610NHLBI NIH HHS R01 HL085757NIDDK NIH HHS K23 DK107908NIDDK NIH HHS R01 DK096549NIDDK NIH HHS R01 DK108803NIDDK NIH HHS R01 DK112258NIDDK NIH HHS T32 DK007757NIDDK NIH HHS U01 DK106962NIDDK NIH HHS U01 DK116100NIGMS NIH HHS R01 GM106085NIOSH CDC HHS U01 OH011326
6 · The paper itself

Abstract

objectiveElectronic health record (EHR) systems contain structured data (such as diagnostic codes) and unstructured data (clinical documentation). Clinical insights can be derived from analyzing both. The use of natural language processing (NLP) algorithms to effectively analyze unstructured data has been well demonstrated. Here we examine the utility of NLP for the identification of patients with non-alcoholic fatty liver disease, assess patterns of disease progression, and identify gaps in care related to breakdown in communication among providers. MATERIALS AND

methodsAll clinical notes available on the 38,575 patients enrolled in the Mount Sinai BioMe cohort were loaded into the NLP system. We compared analysis of structured and unstructured EHR data using NLP, free-text search, and diagnostic codes with validation against expert adjudication. We then used the NLP findings to measure physician impression of progression from early-stage NAFLD to NASH or cirrhosis. Similarly, we used the same NLP findings to identify mentions of NAFLD in radiology reports that did not persist into clinical notes.

resultsOut of 38,575 patients, we identified 2,281 patients with NAFLD. From the remainder, 10,653 patients with similar data density were selected as a control group. NLP outperformed ICD and text search in both sensitivity (NLP: 0.93, ICD: 0.28, text search: 0.81) and F2 score (NLP: 0.92, ICD: 0.34, text search: 0.81). Of 2281 NAFLD patients, 673 (29.5%) were believed to have progressed to NASH or cirrhosis. Among 176 where NAFLD was noted prior to NASH, the average progression time was 410 days. 619 (27.1%) NAFLD patients had it documented only in radiology notes and not acknowledged in other forms of clinical documentation. Of these, 170 (28.4%) were later identified as having likely developed NASH or cirrhosis after a median 1057.3 days. DISCUSSION: NLP-based approaches were more accurate at identifying NAFLD within the EHR than ICD/text search-based approaches. Suspected NAFLD on imaging is often not acknowledged in subsequent clinical documentation. Many such patients are later found to have more advanced liver disease. Analysis of information flows demonstrated loss of key information that could have been used to help prevent the progression of early NAFLD (NAFL) to NASH or cirrhosis.

conclusionFor identification of NAFLD, NLP performed better than alternative selection modalities. It then facilitated analysis of knowledge flow between physician and enabled the identification of breakdowns where key information was lost that could have slowed or prevented later disease progression.

Indexed as

Electronic Health RecordsNatural Language ProcessingAlgorithmsCohort StudiesDisease ProgressionFemaleHumansMaleMiddle AgedNon-alcoholic Fatty Liver DiseaseNAFLDNatural language processingPatient safety

Identifiers

PMID31445275
PMCPMC6717556
OpenAlexW2955111715

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.